Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di)
Titel:
Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di)
Auteur:
Anolli, M.P. Degasperi, E. D'Offizi, G. Brunetto, M.R. Verucchi, G. Federico, A. Ciancio, A. Mangia, A. Santantonio, T.A. Coppola, N. Pellicelli, A. Loglio, A. ViganĂ², M. Pileri, F. Maracci, Monia Puoti, M. Piscaglia, F. Lampertico, P.